

1 **Seroprevalence of Coronavirus Disease 2019 (COVID-19) Among Health Care Workers**  
2 **from Three Pandemic Hospitals of Turkey**

3 **Gizem ALKURT<sup>1\*</sup>, Ahmet MURT<sup>2\*</sup>, Zeki AYDIN<sup>3\*</sup>, Ozge TATLI<sup>4\*</sup>, Nihat Bugra AGAOGLU<sup>1</sup>, Arzu**  
4 **IRVEM<sup>5</sup>, Mehtap AYDIN<sup>6</sup>, Ridvan KARAALI<sup>7</sup>, Mustafa GUNES<sup>8</sup>, Batuhan YESILYURT<sup>9</sup>, Hasan**  
5 **TURKEZ<sup>10</sup>, Adil MARDINOGLU<sup>11,12</sup>, Mehmet DOGANAY<sup>13</sup>, Filiz BASINOGLU<sup>14\*\*</sup>, Nurhan**  
6 **SEYAH<sup>2\*\*</sup>, Gizem DINLER DOGANAY<sup>4\*\*</sup>, Levent DOGANAY<sup>1\*\*</sup>**

7  
8 <sup>1</sup> *Genomic Laboratory (GLAB), Umraniye Teaching and Research Hospital, University of Health Sciences,*  
9 *34760, Istanbul, Turkey*

10 <sup>2</sup> *Department of Nephrology, Cerrahpasa Faculty of Medicine, Istanbul University-Cerrahpasa, 34098,*  
11 *Istanbul, Turkey*

12 <sup>3</sup> *Department of Nephrology, Darica Farabi Teaching and Research Hospital, 41700, Kocaeli, Turkey*

13 <sup>4</sup> *Department of Molecular Biology and Genetics, Istanbul Technical University, 34467, Istanbul, Turkey*

14 <sup>5</sup> *Department of Microbiology, Umraniye Teaching and Research Hospital, University of Health Sciences,*  
15 *34760, Istanbul, Turkey*

16 <sup>6</sup> *Department of Infectious Disease, Umraniye Teaching and Research Hospital, University of Health Sciences,*  
17 *34760, Istanbul, Turkey*

18 <sup>7</sup> *Department of Infectious Disease, Cerrahpasa Faculty of Medicine, Istanbul University-Cerrahpasa, 34098,*  
19 *Istanbul, Turkey*

20 <sup>8</sup> *Department of Urology, Darica Farabi Teaching and Research Hospital, 41700, Kocaeli, Turkey*

21 <sup>9</sup> *Health Institutes of Turkey (TUSEB), 34718, Istanbul, Turkey*

22 <sup>10</sup> *Department of Medical Biology, Faculty of Medicine, Atatürk University, 25240, Erzurum, Turkey*

23 <sup>11</sup> *Science for Life Laboratory, KTH - Royal Institute of Technology, Stockholm, Sweden*

24 <sup>12</sup> *Centre for Host-Microbiome Interactions, Faculty of Dentistry, Oral & Craniofacial Sciences, King's College*  
25 *London, London, SE1 9RT, United Kingdom*

26 <sup>13</sup> *Department of Infectious Diseases, Erciyes University, 38039, Kayseri, Turkey*

27 <sup>14</sup> *Department of Medical Biochemistry, Darica Farabi Teaching and Research Hospital, 41700, Kocaeli,*  
28 *Turkey*

29 **\* These authors contributed to the study equally.**

30 **\*\* These authors have equal correspondence.**

31

32 **Corresponding authors:**

33 Levent DOGANAY, MD. Saglik Bilimleri Universitesi, Umraniye Egitim ve Arastirma Hastanesi,  
34 Gastroenteroloji ve Hepatoloji Klinigi, Istanbul, Turkey. Tel: +90 216 632 18 18-1846 e-mail:  
35 levent.doganay@saglik.gov.tr

36 Gizem DINLER DOGANAY, PhD. Istanbul Teknik Universitesi, Molekuler Biyoloji ve Genetik Bolumu,  
37 Istanbul, Turkey. Tel: +90 212 285 72 50 e-mail: gddoganay@itu.edu.tr

38 Nurhan SEYAHİ, MD. Istanbul Universitesi, Cerrahpasa Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, Nefroloji  
39 Bilim Dalı, Istanbul, Turkey. Tel: +90 212 414 30 00 e-mail: nseyahi@yahoo.com

40 Filiz BASINOĞLU, MD. Darıca Farabi Eğitim ve Araştırma Hastanesi, Tıbbi Biyokimya Bölümü, Kocaeli,  
41 Istanbul, Turkey. Tel: +90 262 656 43 44 e-mail: fbasinoglu@yahoo.com

42

#### 43 **SUMMARY**

44 COVID-19 is a global threat with an increasing number of infections. Research on IgG seroprevalence among  
45 health care workers (HCWs) is needed to re-evaluate health policies. This study was performed in three  
46 pandemic hospitals in Istanbul and Kocaeli. Different clusters of HCWs were screened for SARS-CoV-2  
47 infection. Seropositivity rate among participants was evaluated by chemiluminescent microparticle  
48 immunoassay. We recruited 813 non-infected and 119 PCR-confirmed infected HCWs. Of the previously  
49 undiagnosed HCWs, 22 (2.7%) were seropositive. Seropositivity rates were highest for cleaning staff (6%),  
50 physicians (4%), nurses (2.2%) and radiology technicians (1%). Non-pandemic clinic (6.4%) and ICU (4.3%)  
51 had the highest prevalence. HCWs in “high risk group” had similar seropositivity rate with “no risk” group (2.9  
52 vs 3.6  $p=0.7$ ), indicating the efficient implementation of protection measures in the hospitals in Turkey. These  
53 findings might lead to the re-evaluation of infection control and transmission dynamics in hospitals.

54 **Keywords:** COVID-19; health care workers; HCWs; seroprevalence, SARS-CoV-2, antibody, *coronavirus*

## 55 INTRODUCTION

56 In late 2019, a novel coronavirus (SARS-CoV-2) has emerged in Wuhan, China and posed a global threat to  
57 public health with a quick spread and escalating mortality. As of June, 2020, SARS-CoV-2 related disease  
58 COVID-19 affected more than nine million people worldwide, and caused more than 500 thousand deaths  
59 (WHO, 2020). This is the third coronavirus outbreak that the world has faced in the last two decades, and it  
60 apparently will not be the last.

61 Typical initial clinical signs of COVID-19 have been reported as fever, dry cough, fatigue, headache and  
62 shortness of breath (Guan et al., 2020). Less commonly, diarrhea, nausea and vomiting were also reported as the  
63 atypical symptoms of the disease (Wang et al., 2020b). Older age and comorbid conditions, particularly  
64 hypertension and diabetes increase hospitalization and mortality rates among infected individuals. Unknown  
65 percentage of asymptomatic carriers is another concern due to the difficulty of tracing their contacts with  
66 possible inaccurate calculations of R-naught (Park et al., 2020; Yu and Yang, 2020).

67 Based on genome sequence analysis, SARS-CoV-2 genome was reported to contain 14 Open Reading Frames  
68 (ORFs) encoding 27 proteins (Wu et al., 2020). The lipid envelope of the virus possesses primarily three  
69 structural proteins including membrane (M), envelope (E), and spike (S) proteins. Both S and N proteins have  
70 been reported as highly abundant and immunogenic, which makes them potential targets for serological  
71 diagnosis (Okba et al., 2020). Besides the viral nucleic acid detection based on real-time reverse transcription  
72 polymerase chain reaction (real-time RT-PCR)(Shih et al., 2020), immunoassay tests were recently developed  
73 for accurate detection of IgG and IgM antibodies against SARS-CoV-2 in sera samples. Such tests may help to  
74 eliminate false negatives of RT-PCR tests caused by the difference in the viral load of different respiratory  
75 specimens (Liu et al., 2020). For increased sensitivity in diagnosis of COVID-19, both modalities should be  
76 combined as complementary to each other. Moreover, serologic tests could be utilized for the detection of  
77 overall infection rate in the population (Lou et al., 2020).

78 Istanbul is the epicenter of the ongoing pandemic in Turkey and 60% of the confirmed cases are from Istanbul  
79 (Doganay et al., 2020). In the current study, seroprevalence of COVID-19 specific IgGs was tested among  
80 health care workers (HCWs) from two different pandemic hospitals in Istanbul and one from the neighboring  
81 city of Kocaeli. First COVID-19 case was officially reported on 11 March 2020 in Turkey and since then all  
82 three hospitals had a substantial role with treating more than 40 000 patients during pandemic. We aimed to  
83 identify asymptomatic infections and to assess the risks of contracting COVID-19 among different clusters of  
84 HCWs. Evaluating the prevalence of infection at different parts of the hospitals and the effect of transmission  
85 prevention measures hold great importance for the development of mitigation strategies.

## 86 RESULTS

### 87 *Demographic data*

88 Locations of the three hospitals in Istanbul and Kocaeli were mapped in Figure 1. The timeline showing the  
89 progression of COVID-19 pandemic in Turkey, which includes events from the date that the country's first

90 coronavirus case has been announced, was given in Figure 2. All three pandemic hospitals are tertiary health  
91 care centers with high capacity, employing a total of 8328 HCWs. On the peak day of the pandemic, maximum  
92 hospitalized patient numbers (on a day) reached to 410, 222 and 300 for UEAH, Cerrahpasa and Farabi,  
93 respectively. Total number of hospitalized patients in the hospitals throughout the pandemic was 5437 (Table 1).  
94 Among 8328 HCWs, 932 were enrolled for the study. Demographics, assigned work areas during pandemic,  
95 comorbidities and SARS-CoV-2 IgG positivity according to risk stratification of HCWs were given on Table 2.  
96 Of all participants, the number of personnel classified as “no risk”, “low risk” and “high risk” group were 113  
97 (12.1%), 157 (16.8%) and 543 (58.3%), respectively. Additional 119 HCWs (12.8% of all participants),  
98 previously diagnosed with COVID-19 by RT-PCR, were enrolled and classified as “PCR positive” group. Of  
99 PCR positive HCWs, 103 displayed the clinical signs of COVID-19. 16 (13.4%), who did not have compatible  
100 symptoms, were tested due to the exposure history, and were recorded as asymptomatic. Only one HCW had a  
101 history of admission to ICU, no deaths occurred (Table 1). Of the non-infected HCWs, 597 gave consent for  
102 oro-nasopharyngeal swab sampling and all RT-PCR results were negative.

### 103 *Seroprevalence of HCWs in non-infected group*

104 IgG antibodies against SARS-CoV-2 in serum samples of all participants were detected by chemiluminescent  
105 microparticle immunoassay. The rate of seroprevalence was 2.7% among non-infected HCWs (Table S2). The  
106 seropositivity rate was 3.5%, 1.3%, 2.9% in “no risk”, “low risk” and “high risk” groups, respectively ( $p=0.4$ ).  
107 Among three hospitals, Cerrahpasa had the highest seroprevalence (7.2%,  $p<0.001$ ) (Table 3/Figure S1). The  
108 seropositivity rate in Cerrahpasa was statistically significantly different when compared to UEAH ( $p<0.01$ ) and  
109 Farabi ( $p<0.001$ ). Of 307 HCWs in Farabi, only one tested positive, yielding the lowest seropositivity rate of the  
110 hospitals (0.3%) (Figure 3). Although the seroprevalence was not significantly different among professions, it  
111 was highest among cleaning staff (6%) (Figure 4). Interestingly, the seropositivity rate of the workers employed  
112 in non-pandemic clinics (6.4%) was higher than those working in other areas ( $p=0.05$ ) (Table 4/Figure 5).

### 113 *Seroprevalence of PCR positive group*

114 To assess antibody production in COVID-19 patients, we analyzed the positive rates of IgGs in sera of all  
115 HCWs after  $52.8\pm 11.6$  days post-infection. IgGs for SARS-CoV-2 were detected in 78.2% of convalescent  
116 COVID-19 patients (Table S1). Among PCR positive group, those had CT findings compatible with COVID-19,  
117 had higher seropositivity ( $p<0.001$ ). IgG titers in asymptomatic PCR positive patients were significantly lower  
118 than symptomatic ones ( $p=0.008$ ). There were 10 HCWs with IgG titers between 1.4-1.0 S/C. If the cut off was  
119 set to 1.0 S/C, seropositivity in this risk group would have increased to 82.3%.

## 120 **DISCUSSION**

121 Health care systems are under tremendous pressure due to the lack of curative treatment for COVID-19.(Wang  
122 et al., 2020a) Protection of first-line HCWs from the infection is of utmost importance to provide sustainable  
123 public health services. High burden of COVID-19 disease in hospitals worldwide has been explored in several  
124 studies. In Spain, one of the European countries hardest-hit by COVID-19, the nationwide seroprevalence for  
125 SARS-CoV-2 tested by chemiluminescent microparticle immunoassay was found to be around 5%. For HCWs,

126 the seroprevalence has surpassed the national rate and reached over 8%.(Pollán et al., 2020) Of HCWs in a  
127 tertiary hospital in Belgium, seroprevalence detected by rapid cassette test was 6.4%.(Steensels et al., 2020) In  
128 another study conducted in Wuhan, 1.1% of HCWs tested positive in their swab samples by RT-PCR (Lai et al.,  
129 2020). 0.89% of HCWs in two hospitals in Netherlands had positive RT-PCR results for COVID-19  
130 (Kluytmans-van den Bergh et al., 2020). In this study, even though the percentage of HCWs infected with  
131 COVID-19 in the three pandemic hospitals is also noteworthy (2.7%), the insignificant difference between no-  
132 risk and high-risk group implied that the protection measures are reassuringly rigorous to prevent the  
133 transmission of SARS-CoV-2 in these hospitals.

134 HCWs employed in coronavirus testing labs (Corona lab) and swab teams were reasonably anticipated to be at  
135 high risk. In this study, we did not observe seropositivity in these personnel, they were found to be efficiently  
136 protected from the disease. However, non-clinical healthcare workers such as cleaning staff were found to be  
137 more prominently affected from the transmission possibly due to the inadequate compliance with the infection  
138 control. Thus, all staff in hospitals should be well-trained on elements of disease transmission; such as the  
139 sources of exposure to the virus, risks associated with the exposure and suitable occupational protocols. Besides,  
140 the workers in non-pandemic clinics were apparently exposed to the virus regardless of specific exposure risk.  
141 Such data implied that the risk of viral transmission in these areas are widely underestimated and utmost caution  
142 is urged in all zones of the hospitals.

143 Limited data are available for asymptomatic or subclinical infections in transmission of SARS-CoV-2 virus  
144 (Weitz et al., 2020). Here, 13.4% of the PCR-confirmed HCWs with infection never developed any COVID-19  
145 relevant symptoms and remained asymptomatic. Besides, a substantial number of undiagnosed HCWs were  
146 seropositive indicating the recovery from COVID-19 without any clinical signs of the disease. These  
147 asymptomatic carriers who remained undiagnosed throughout the infection may be the silent sources of virus  
148 spread among HCWs. The finding that IgG levels of asymptomatic individuals were lower than that of  
149 symptomatic ones is in line with the previous findings suggesting that asymptomatic carriers have a weaker  
150 humoral immune response to COVID-19 infection (Long et al., 2020). Similarly, seropositivity rate was  
151 statistically significantly higher in those with compatible CT scan findings, indicating that the severity of the  
152 disease is positively correlated with the potency of immunity. Such a finding is similar to that were reported for  
153 SARS-CoV and MERS-CoV, for whom higher levels of IgM and IgGs have also been shown to be correlated  
154 with the severity of disease (Alshukairi et al., 2016; Lee et al., 2006; Zhang et al., 2020; Zhao et al., 2020).

155 Although overall seropositivity among HCWs was calculated as 2.7% in our study, fluctuations between  
156 institutions were also noted. A lower rate at Farabi (0.3%) might be presumable, as PCR confirmed HCW rate  
157 was also not that high (0.5%). On the other hand, between two institutions with comparable PCR confirmed  
158 HCW rates, observed seropositivity of HCWs from Cerrahpasa was found to be significantly higher than those  
159 from UEAH (7.2% and 1.5% respectively). As we compared the work schedules of HCWs in three hospitals, we  
160 noticed that physicians in Cerrahpasa was assigned to the pandemic clinics on daily basis. On the other days of  
161 the week the same physician served at non-pandemic clinic, too. The work schedule was made on monthly basis  
162 in UEAH and Farabi. Moreover, at Cerrahpasa as being a distinguished medical school, teaching on ward  
163 rounds with medical students continuous took place until 18<sup>th</sup> of March. UEAH and Farabi do not teach

164 undergraduate students. Cerrahpasa's buildings were being reconstructed when the outbreak began in Turkey  
165 and this might have also impaired some infection control measures.

166 In 21.8% of PCR-confirmed COVID-19 patients, IgG titers were found to be below 1.4 S/C which was denoted  
167 as the cut-off value of positivity by the manufacturer. Previous studies with RT-PCR positive patients have only  
168 enrolled patients with clear clinical findings (Boise et al., 2020). It is possible that the cut off might be too  
169 stringent for asymptomatic patients. Thus, a number of asymptotically recovered HCWs with COVID-19 in  
170 high-risk group might be also remained undetected in serodiagnosis. If the cut-off was set to 1.0 S/C the  
171 seropositivity in high risk group would have increased from 2.9% to 3.9%.

172 The information for SARS-CoV-2 transmission among health care workers could help for the revision of health  
173 policies and immunization strategies in hospitals for a possible resurgence of the outbreak. Further, extensive  
174 knowledge of antibody seroconversion and characterization of antibody profiles throughout SARS-CoV-2  
175 infection could provide insights for the identification of potentially targeted neutralizing antibodies.

## 176 **Limitations**

177 Even though a significant number of employees were tested, not all of the invited HCWs in these hospitals  
178 participated in the study. Screening larger cohorts from hospitals could serve more information to monitor the  
179 course of pandemic among HCWs.

180

## 181 **METHODS**

### 182 **Study Design and Participants**

183 This study was conducted in three pandemic hospitals in Istanbul and Kocaeli, including University of Health  
184 Sciences Umraniye Teaching and Research Hospital (UEAH), Istanbul University-Cerrahpasa, Cerrahpasa  
185 Medical Faculty Hospital (Cerrahpasa), Darica Farabi Teaching and Research Hospital (Farabi). HCWs were  
186 invited to participate in the study. Exposure risk of the HCWs was determined by the working areas they were  
187 assigned during the pandemic. Some HCWs were on administrative leave due to their medical conditions and  
188 they were classified as having "no risk". HCWs working in the clinics, which were kept clear of COVID-19 or  
189 had no direct contact with any patient, were classified as having "low risk". HCWs employed in hot zones for  
190 COVID-19 transmission including emergency unit, intensive care unit (ICU), pandemic clinics, COVID  
191 outpatient clinics, COVID testing labs, departments of Infectious Diseases and Chest Medicine, and radiology  
192 department (where CT scans and chest X-rays were performed) were classified as having "high risk". HCWs  
193 with administrative roles for supervising hot zones with regular visits were also classified in the "high risk"  
194 group. We also recruited HCWs who were diagnosed with COVID-19 at least 14 days before enrollment for the  
195 study. This group was defined as the "PCR positive" group. Demographics data, comorbidities, drug history,  
196 date of COVID-19 diagnosis, past PCR tests, results of chest computed tomography (CT) scans were noted.  
197 HCWs not willing to give consent, HCWs with a history of COVID-19 diagnosis without a confirmatory PCR  
198 test and those diagnosed within the last 14 days were excluded. All blood samples were collected in the three  
199 hospitals in between 30<sup>th</sup> May and 6<sup>th</sup> of June 2020. Oro-nasopharyngeal swab samples of the three subgroups



200 (excluding PCR positive group) were also tested to confirm the absence of active infection at the time when  
201 blood specimens were collected.

202 All sera samples were aliquoted after centrifugation of peripheral blood tubes at 800xg for 12 minutes and sera  
203 samples were kept in -20°C until the study day. For detection of SARS-CoV-2 IgG, chemiluminescent  
204 microparticle immunoassay was carried out according to manufacturer's instructions and samples were run on  
205 the related instrument (ARCHITECT, Abbott Laboratories, Abbott Park, IL, USA). Minimum 100 µL of serum  
206 was required for analysis. Qualitative results were reported by the instrument with the cut-off value of 1.40 S/C  
207 as recommended. This study was approved by the ethics committee of the Umraniye Teaching and Research  
208 Hospital (approval number: 29.05.2020/10337). Written informed consent was obtained from each enrolled  
209 participant. All study was carried out in accordance with the ethical standards of the Helsinki Declaration.

## 210 **Statistical Analysis**

211 All statistical analyses were performed by SPSS version 22 software (Chicago, IL). Parametric variables were  
212 analyzed by Student's *t*-test. Mann-Whitney U test was employed for nonparametric continuous variables.  
213 Categorical variables were tested by using the chi-square and Fisher's exact test. Two-sided *p* value below 0.05  
214 was considered to be statistically significant.

215  
216

## 217 **REFERENCES**

- 218 Alshukairi, A.N., Khalid, I., Ahmed, W.A., Dada, A.M., Bayumi, D.T., Malic, L.S., Althawadi, S., Ignacio, K.,  
219 Alsalmi, H.S., Al-Abdely, H.M., et al. (2016). Antibody response and disease severity in healthcare worker  
220 MERS survivors. *Emerg. Infect. Dis.* 22, 1113–1115.
- 221 Boise, in, Bryan, A., Pepper, G., Wener, M.H., Fink, S.L., Morishima, C., Jerome, K.R., Mathias, P.C., and  
222 Greninger, A.L. (2020). Performance Characteristics of the Abbott Architect SARS-CoV-2 IgG Assay and  
223 Seroprevalence 1 Downloaded from. *J. Clin. Microbiol.*
- 224 Doganay, L. (2020). Responding to Covid-19 in Istanbul: Perspective from Genomic Laboratory. *North. Clin.*  
225 *Istanbul* 7, 311.
- 226 Guan, W., Ni, Z., Hu, Y., Liang, W., Ou, C., He, J., Liu, L., Shan, H., Lei, C., Hui, D.S.C., et al. (2020). Clinical  
227 Characteristics of Coronavirus Disease 2019 in China. *N. Engl. J. Med.* 382, 1708–1720.
- 228 Kluytmans-van den Bergh, M.F.Q., Buiting, A.G.M., Pas, S.D., Bentvelsen, R.G., van den Bijllaardt, W., van  
229 Oudheusden, A.J.G., van Rijen, M.M.L., Verweij, J.J., Koopmans, M.P.G., and Kluytmans, J.A.J.W. (2020).  
230 Prevalence and Clinical Presentation of Health Care Workers With Symptoms of Coronavirus Disease 2019 in 2  
231 Dutch Hospitals During an Early Phase of the Pandemic. *JAMA Netw. Open* 3, e209673.
- 232 Lai, X., Wang, M., Qin, C., Tan, L., Ran, L., Chen, D., Zhang, H., Shang, K., Xia, C., Wang, S., et al. (2020).

- 233 Coronavirus Disease 2019 (COVID-2019) Infection Among Health Care Workers and Implications for  
234 Prevention Measures in a Tertiary Hospital in Wuhan, China. *JAMA Netw. Open* 3, e209666.
- 235 Lee, N., Chan, P.K.S., Ip, M., Wong, E., Ho, J., Ho, C., Cockram, C.S., and Hui, D.S. (2006). Anti-SARS-CoV  
236 IgG response in relation to disease severity of severe acute respiratory syndrome. *J. Clin. Virol.* 35, 179–184.
- 237 Liu, W., Liu, L., Kou, G., Zheng, Y., Ding, Y., Ni, W., Wang, Q., Tan, L., Wu, W., Tang, S., et al. (2020).  
238 Evaluation of Nucleocapsid and Spike Protein-Based Enzyme-Linked Immunosorbent Assays for Detecting  
239 Antibodies against SARS-CoV-2. *J. Clin. Microbiol.* 58.
- 240 Long, Q.-X., Tang, X.-J., Shi, Q.-L., Li, Q., Deng, H.-J., Yuan, J., Hu, J.-L., Xu, W., Zhang, Y., Lv, F.-J., et al.  
241 (2020). Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections. *Nat. Med.* 1–5.
- 242 Lou, B., Li, T.-D., Zheng, S.-F., Su, Y.-Y., Li, Z.-Y., Liu, W., Yu, F., Ge, S.-X., Zou, Q.-D., Yuan, Q., et al.  
243 (2020). Serology characteristics of SARS-CoV-2 infection since the exposure and post symptoms onset.  
244 *MedRxiv* 2020.03.23.20041707.
- 245 Okba, N.M.A., Müller, M.A., Li, W., Wang, C., GeurtsvanKessel, C.H., Corman, V.M., Lamers, M.M.,  
246 Sikkema, R.S., de Bruin, E., Chandler, F.D., et al. (2020). Severe Acute Respiratory Syndrome Coronavirus 2-  
247 Specific Antibody Responses in Coronavirus Disease 2019 Patients. *Emerg. Infect. Dis.* 26.
- 248 Park, S.W., Cornforth, D.M., Dushoff, J., and Weitz, J.S. (2020). The time scale of asymptomatic transmission  
249 affects estimates of epidemic potential in the COVID-19 outbreak. *MedRxiv* 2020.03.09.20033514.
- 250 Pollán, M., Pérez-Gómez, B., Pastor-Barriuso, R., Oteo, J., Hernán, M.A., Pérez-Olmeda, M., Sanmartín, J.L.,  
251 Fernández-García, A., Cruz, I., Fernández de Larrea, N., et al. (2020). Prevalence of SARS-CoV-2 in Spain  
252 (ENE-COVID): a nationwide, population-based seroepidemiological study. *Lancet* 0.
- 253 Shih, H.I., Wu, C.J., Tu, Y.F., and Chi, C.Y. (2020). Fighting COVID-19: A quick review of diagnoses,  
254 therapies, and vaccines. *Biomed. J.*
- 255 Steensels, D., Oris, E., Coninx, L., Nuyens, D., Delforge, M.-L., Vermeersch, P., and Heylen, L. (2020).  
256 Hospital-Wide SARS-CoV-2 Antibody Screening in 3056 Staff in a Tertiary Center in Belgium. *JAMA.*
- 257 Wang, D., Hu, B., Hu, C., Zhu, F., Liu, X., Zhang, J., Wang, B., Xiang, H., Cheng, Z., Xiong, Y., et al. (2020a).  
258 Clinical Characteristics of 138 Hospitalized Patients with 2019 Novel Coronavirus-Infected Pneumonia in  
259 Wuhan, China. *JAMA - J. Am. Med. Assoc.* 323, 1061–1069.
- 260 Wang, J., Zhou, M., and Liu, F. (2020b). Reasons for healthcare workers becoming infected with novel  
261 coronavirus disease 2019 (COVID-19) in China. *J. Hosp. Infect.* 105, 100–101.
- 262 Weitz, J.S., Beckett, S.J., Coenen, A.R., Demory, D., Dominguez-Mirazo, M., Dushoff, J., Leung, C.Y., Li, G.,  
263 Măgălie, A., Park, S.W., et al. (2020). Modeling shield immunity to reduce COVID-19 epidemic spread. *Nat.*  
264 *Med.* 26, 849–854.



265 Wu, A., Peng, Y., Huang, B., Ding, X., Wang, X., Niu, P., Meng, J., Zhu, Z., Zhang, Z., Wang, J., et al. (2020).  
266 Genome Composition and Divergence of the Novel Coronavirus (2019-nCoV) Originating in China. *Cell Host*  
267 *Microbe* 27, 325–328.

268 Yu, X., and Yang, R. (2020). COVID-19 transmission through asymptomatic carriers is a challenge to  
269 containment. *Influenza Other Respi. Viruses* 14, 474.

270 Zhang, B., Zhou, X., Zhu, C., Feng, F., Qiu, Y., Feng, J., Jia, Q., Song, Q., Zhu, B., and Wang, J. (2020).  
271 Immune phenotyping based on neutrophil-to-lymphocyte ratio and IgG predicts disease severity and outcome  
272 for patients with COVID-19. *MedRxiv* 2020.03.12.20035048.

273 Zhao, J., Yuan, Q., Wang, H., Liu, W., Liao, X., Su, Y., Wang, X., Yuan, J., Li, T., Li, J., et al. (2020).  
274 Antibody responses to SARS-CoV-2 in patients of novel coronavirus disease 2019. *MedRxiv*.

275 WHO Coronavirus Disease (COVID-19) Dashboard | WHO Coronavirus Disease (COVID-19) Dashboard.

## 276 **ACKNOWLEDGMENTS**

277 We appreciate the generous contribution of Abbott for providing Architect SARS-CoV-2 IgG antibody kits, the  
278 chemiluminescence microparticle immunoassay method, to our institutions. We thank Yesim Karaca, Aleyna  
279 Karaca, İrem Yaren Nur and Murat Kaya for technical assistance.

280

## 281 **AUTHOR CONTRIBUTIONS**

282 GA was responsible for the analysis and interpretation of the data, drafting the manuscript and literature search.  
283 AhM was responsible for data acquisition, analysis, drafting the manuscript and literature search. ZA  
284 participated to the data acquisition, literature search and study design. OT was responsible for interpreting the  
285 data, drafting the manuscript and searching the literature. NBA, AI and MG collected data and participated to  
286 the analysis. MA and RK were responsible for data acquisition. BY contributed to the design and coordination  
287 of the study. HT and AdM coordinated and operated the study. MD interpreted the collected data. FB and NS  
288 collected data, designed and coordinated the study. GDD contributed to the study design and manuscript  
289 drafting. LD was the coordinator of the project and was responsible for acquisition, interpretation and analysis  
290 of the data and drafting the manuscript. All authors critically reviewed the draft and approved the final version  
291 for publication.

292

## 293 **COMPETING INTERESTS**

294 The authors declare that they have no competing interests.

## 295 **FIGURE TITLES AND LEGENDS**

296 **Figure 1:** Location of three pandemic hospitals

297 **Figure 2:** Timeline of COVID19 in three pandemic hospital

298 **Figure 3:** Seropositivity results of non-infected HCW in three pandemic hospitals

299 **Figure 4:** Seropositivity results of non-infected HCW according to profession

300 **Figure 5:** Seropositivity results of non-infected HCW according to assigned working areas

301 **TABLES**

302 **Table 1. Characteristics of the Health Care Facilities**

	<b>Hospitals</b>			<b>Total</b>
	<b>UEAH</b>	<b>Cerrahpasa</b>	<b>Farabi</b>	
<b>Number of Hospital Beds</b>	836	880	350	2066
<b>Maximum Number of Hospitalized Patient with COVID-19 (at the peak day)</b>	410	222	300	932
<b>Total Number of Hospitalized Patient with COVID-19</b>	2528	1056	1853	5437
<b>Total Number of Patients Visits at COVID-19 Outpatient Clinic</b>	14906	21970	12375	49251
<b>Number of HCWs</b>	3232	3723	1373	8328
<b>HCWs diagnosed with COVID-19</b>	125 (3.8%)	107 (2.8%)	14 (1%)	241 (2.8%)
<b>PCR Positive HCWs</b>	105 (3.2%)	84 (2.2%)	8 (0.5%)	187 (2.2%)
<b>Hospitalized HCWs in ICU</b>	1	0	0	1
<b>Number of Deaths in infected HCWs</b>	0	0	0	0

303 All data is given for the period between 1 March and 30 May 2020. HCW: Health Care Worker

304 **Table 2: Demographics and seropositivity of front-line and non-front-line HCWs**

Characteristics	Health Care Workers				Total n=932 (%)
	No Risk n=113 (%)	Low Risk n=157 (%)	High Risk n=543 (%)	PCR Positive n=119 (%)	
<b>Hospital</b>					
UEAH	52 (46.0)	0	218 (40.1)	52 (43.7)	322 (34.5)
Cerrahpasa	58 (51.3)	54 (34.4)	124 (22.8)	64 (53.8)	300 (32.2)
Farabi	3 (2.7)	103 (65.6)	201 (37.0)	3 (2.5)	310 (33.3)
<b>Age, Mean±SD</b>	34.5± 12.23	35.5± 8.86	34.3± 8.92	36.2± 10.14	34.8± 9.54
<b>Sex</b>					
Male	56 (49.6)	53 (33.8)	184 (33.9)	39 (32.8)	332 (35.6)
Female	57 (50.4)	104 (66.2)	359 (66.1)	80 (67.2)	600 (64.4)
<b>Profession</b>					
Physician	62 (54.9)	12 (7.6)	175 (32.2)	30 (25.2)	279 (29.9)
Nurse	17 (15.0)	32 (20.4)	174 (32.0)	45 (37.8)	268 (28.8)
Ward Clerk&Security	12 (10.6)	67 (42.7)	35 (6.4)	15 (12.6)	129 (13.8)
Lab&Radiology Technician	1 (0.9)	7 (4.5)	92 (16.9)	7 (5.9)	107 (11.5)
Cleaning Staff	12 (10.6)	10 (6.4)	62 (11.4)	12 (10.1)	96 (10.3)
Administrative Staff	9 (8.0)	29 (18.5)	5 (0.9)	10 (8.4)	53 (5.7)
<b>Assigned Department</b>					
Pandemic Clinic	0	0	284 (52.3)	51 (42.8)	335 (35.9)
Intensive Care Unit	0	0	69 (12.7)	10 (8.4)	79 (8.5)
Emergency Room	0	0	47 (8.7)	8 (6.7)	55 (5.9)
Corona Lab	0	0	61 (11.2)	1 (0.8)	62 (6.7)
Swab Team	0	0	51 (9.4)	4 (3.4)	55 (5.9)
Non-Pandemic Clinic	0	50 (31.9)	28 (5.1)	30 (25.2)	108 (11.6)
Administrative Office	0	107 (68.2)	3 (0.6)	15 (12.6)	125 (13.4)
On leave	113 (100)	0	0	0	113 (12.1)
<b>Clinical Information</b>					
Chronic Disease Present	31 (27.4)	19 (12.1)	61 (11.2)	31 (26.1)	142 (15.2)
Hypertension	8 (7.1)	7 (4.5)	19 (3.5)	7 (5.9)	41 (4.4)
Diabetes Mellitus	5 (4.4)	2 (1.3)	16 (2.9)	6 (5.0)	29 (3.1)
Other Chronic Disease	22 (19.5)	11 (7.0)	29 (5.3)	19 (16.0)	81 (8.7)
ACE inh./ARB	6 (5.3)	5 (3.2)	16 (2.9)	8 (6.7)	35 (3.8)
Immuno-suppressive drug	2 (1.8)	1 (0.6)	2 (0.4)	2 (1.7)	7 (0.8)
Smoking	25 (22.1)	42 (26.8)	147 (27.1)	14 (11.8)	228 (24.5)
<b>IgG Positive</b>	4 (3.5)	2 (1.3)	16 (2.9)	93 (78.2)	115 (12.3)
Symptoms	n.a.	n.a.	n.a.	98 (82.4)	98 (10.5)
CT Result	n.a.	n.a.	n.a.	71 (59.7)	71 (7.6)

305 ACE inh.: Angiotensin-converting enzyme (ACE) inhibitor, ARB: Angiotensin II receptor blocker,

306 CT: Computed tomography scan, HCW: Health Care Worker, n.a: not applicable

307

308

309

310

311

312

313

314

315

316

317

318

319

320

321 **Table 3: Seropositivity among risk groups**

Characteristic	No Risk n=113 (%)	Low Risk n=157 (%)	High Risk n=543 (%)	Total n=813 (%)
<b>IgG Positive</b>	4 (3.5)	2 (1.3)	16 (2.9)	22 (2.7)
<b>Hospital</b>				
UEAH	1 (1.9)	N/A	3 (1.3)	4 (1.5)
Cerrahpasa	3 (5.1)	2 (3.7)	12 (9.6)	17 (7.2)
Farabi	0	0	1 (0.4)	1 (0.3)
<b>IgG Titration, mean±SD</b>	0.4 ±0.18	0.3 ±0.11	0.1 ±0.16	0.3 ±0.16

322 N/A: Not Available

323

324

325

326 **Table 4: Seropositivity among assigned working areas and profession**

Characteristic n (%)	IgG Negative n=791	IgG Positive n=22	OR	95% CI	p value
<b>Profession</b>					
Physician	239 (96.0)	10 (4.0)	1.93	0.82- 4.51	0.16
Nurse	218 (97.7)	5 (2.2)	0.77	0.28-2.12	0.81
Ward Clerk&Security	113 (99.1)	1 (0.9)	0.29	0.04-2.15	0.35
Lab&Radiology Technician	99 (99.0)	1 (1.0)	0.33	0.04-2.50	0.51
Cleaning Staff	79 (94.0)	5 (6.0)	2.65	0.95-7.38	0.07
Administrative Staff	43 (100)	0	n.a.	n.a.	0.62
<b>Assigned Department</b>					
Pandemic Clinic	276 (96.8)	9 (3.2)	1.3	0.55-3.08	0.65
Intensive Care Unit	66 (95.6)	3 (4.3)	1.73	0.5-6.01	0.42
Emergency Room	46 (97.9)	1 (2.1)	0.77	0.10-5.86	1.00
Corona Lab	61 (100)	0	n.a.	n.a.	0.4
Swab Team	51 (100)	0	n.a.	n.a.	0.63
Non-Pandemic Clinic	73 (93.6)	5 (6.4)	2.89	1.04-8.61	0.05
Administration Office	111 (100)	0	n.a.	n.a.	0.06
On leave	107 (96.4)	4 (3.6)	1.39	0.46-4.19	0.53

327 n.a: not applicable, OR: Odd Ratio, CI: Confidence Interval

328

329

330 **SUPPLEMENTARY DATA**

331

332 **Figure S1:** Result of IgG titration means according to risk groups

333

334 **Table S1:** IgG titration values of “PCR positive” group

335

336 **Table S2:** IgG titration values of seropositive non-infected HCWs



EUROPE

ISTANBUL

BLACKSEA

KOCAELI

CERRAHPASA




UEAH

ASIA




FARABI


SEA OF MARMARA







Profession



Percentage of seropositive  
non-COVID19 HCW

